Abstract

The medical device industry has contributed new technologies applied in medicine, and the demand for advanced biomaterial development is increasing. However, a significant gap exists between the research and final product production during the commercialization process of medical devices. To establish a comprehensive industrial ecosystem and key technologies for biomaterial development, the High-value Biomaterials Research and Commercialization Center (HBRCC, also known as MT3+) assists researchers and industries in optimizing formulas and mass production of powder/granule or liquid/gel biomaterials to derive high-value biomedical implants. Additionally, HBRCC focuses on the design and development of delivery devices for implants. Our team has some experience in developing biomaterial medical devices rapidly including barbed sutures, contact lens care solutions, and bone graft materials. Especially it only took our team 2 years from developing the prototype of barbed sutures to obtaining TFDA approval, and helped the biomaterial distributor to launch the commercial medical device onto the market. HBRCC commits to facilitating alliances and promoting the development of the biomaterials industry by dedicating itself to research and development, consulting with follow-up plans, expanding promotional activities, and strengthening capabilities in the field of biomaterials engineering, thereby improving the competitiveness of Taiwanese biomedical industries.